When is tedizolid used to treat enterococcal infections?

Updated: Jun 10, 2021
  • Author: Susan L Fraser, MD; Chief Editor: John L Brusch, MD, FACP  more...
  • Print

Tedizolid, a newly approved oxazolidinone antibiotic, is indicated for skin and skin structure infections caused by susceptible isolates of gram-positive bacteria. Susceptible microorganisms include S aureus (including MRSA and methicillin-susceptible [MSSA] isolates), S pyogenes, S agalactiae, S anginosus group (including S anginosus, S intermedius, and S constellatus), and E faecalis. Its action is mediated by binding to the 50S subunit of the bacterial ribosome, resulting in inhibition of protein synthesis. It can be taken by mouth or IV every day for 6 days. Approval for tedizolid was based on 2 clinical trials including more than 1300 participants that showed it to be noninferior to linezolid. [57, 58]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!